Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine

Kidney International

Volumn 72, Issue 3, 2007, Pages 359-363

  Feldman, L ^a   Efrati, S ^a   Eviatar, E ^a   Abramsohn, R ^a   Yarovoy, I ^a   Gersch, E ^a   Averbukh, Z ^a   Weissgarten, J ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Gentamicin; Hemodialysis; N acetylcysteine; Ototoxicity

Indexed keywords

ACETYLCYSTEINE; CEFAZOLIN; GENTAMICIN; SIRAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUDIOMETRY; BACTEREMIA; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEARING LOSS; HEMODIALYSIS; HUMAN; MALE; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TINNITUS; VERTIGO;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; BACTEREMIA; CYSTEINE; FEMALE; GENTAMICINS; GLUTATHIONE; HEARING LOSS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 34547479230     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002295     Document Type: Article

References (32)

1. Gilbert D. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, (eds). Principles and Practice of Infectious Diseases. 6th edn, Churchill Livingstone: New York, 2005, pp 328-356.
2. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci 1999; 884: 15-18.
3. Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986; 80: 98-104.
4. Black FO, Pesznecker SC. Vestibular ototoxicity. Clinical considerations. Otolaryngol Clin North Am 1993; 26: 713-736.
5. Fausti S, Henry J, Schaffer H et al. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992; 165: 1026-1032.
6. Gailiunas P, Dominques-Moreno M, Lazarus M et al. Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy. Arch Intern Med 1978; 138: 1621-1624.
7. Black F, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol 2004; 25: 559-569.
8. Munckhof W, Grayson M, Turnidge J. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-663.
9. Wu W, Sha S, Schacht J. Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol Neurootol 2002; 7: 171-174.
10. Sinswat P, Wu W, Sha S, Schacht J. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int 2000; 58: 2525-2532.
11. Sha S, Qiu J, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006; 354: 1856-1857.
12. Prescott L, Illingworth R, Critchey J et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. BMJ 1979; 2: 1097-1100.
13. Arstall M, Yang J, Stafford I et al. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Circulation 1995; 92: 2855-2862.
14. Weinbroum A, Rudick V, Ben-Abraham R, Karchevski E. N-acetyl- L-cysteine for preventing lung reperfusion injury after liver ischemia-reperfusion - a possible dual protective mechanism in a dose-response study. Transplantation 2000; 69: 853-859.
15. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
16. Klein M, Koedel U, Pfister H, Kastenbauer S. Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy. Ann Neurol 2003; 54: 451-458.
17. Feghali J, Liu W, Van De Water T. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 2001; 111: 1147-1155.
18. Mazzon E, Britti D, De Sarro A et al. Effect of N-acetylcysteine on gentamycin-mediated nephropathy in rats. Eur J Pharmacol 2001; 424: 75-83.
19. Ramsey B, Pepe M, Quan J et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
20. Drobnic M, Sune P, Montoro J et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39: 39-44.
21. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
22. Piraino B, Bailie G, Bernardini J et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-131.
23. Saad T. Central venous dialysis catheters: catheter-associated infection. Semin Dial 2001; 14: 446-451.
24. Aran J. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg 1995; 112: 133-144.
25. Farr S, Poon H, Dogrukol-Ak D et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003; 84: 1173-1183.
26. Pendyala L, Creaven P. Pharmacokinetic and pharmacodynamic studies of N-acetylcycteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev 1995; 4: 245-251.
27. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280.
28. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218.
29. Tepel M, Van der Giet M, Statz M et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995.
30. Yusuf S, Dagenais G, Pogue J et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-160.
31. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994; 36(Suppl ): 11-19.
32. National Kidney Foundation. K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis 2001; 37(Suppl ): S7-S64.